63981-31-7

Basic information

• Product Name: 6-Amino-1-ethyl-3-propyluracil
• Synonyms: 6-Amino-1-ethyl-3-propyluracil;Brn 0162762;Uracil, 6-amino-1-ethyl-3-propyl-;6-aMino-1-ethyl-3-propyl-1,2,3,4- tetrahydropyriMidine-2,4-dione;6-AMino-1-ethyl-3-propyl-2,4(1H,3H)-pyriMidinedione;1-Ethyl-3-propyl-6-aminouracil
• CAS NO: 63981-31-7
• Molecular Formula: C9H15 N3 O2
• Molecular Weight: 197.2343
• Product Categories: Amines, Nucleotides, Bases & Related Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 63981-31-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 292.4°Cat760mmHg
• Flash Point: 130.6°C
• Appearance: /
• Density: 1.146g/cm³
• Vapor Pressure: 0.00184mmHg at 25°C
• Refractive Index: 1.519
• CAS DataBase Reference: 6-Amino-1-ethyl-3-propyluracil(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Amino-1-ethyl-3-propyluracil(63981-31-7)
• EPA Substance Registry System: 6-Amino-1-ethyl-3-propyluracil(63981-31-7)

Safety Data

• Hazardous Substances Data: 63981-31-7(Hazardous Substances Data)

Usage

Description

6-Amino-1-ethyl-3-propyluracil is an organic compound that serves as an intermediate in the synthesis of a series of new substituted Xanthines. These Xanthines exhibit high affinity and selectivity for the human adenosine A2B receptors, making them potential candidates for clinical applications in treating chronic inflammatory airway diseases.

Uses

Used in Pharmaceutical Industry:
6-Amino-1-ethyl-3-propyluracil is used as an intermediate in the synthesis of Xanthines for the development of clinical candidates. These Xanthines target the human adenosine A2B receptors, which play a crucial role in modulating inflammatory responses in airway diseases. By selectively binding to these receptors, the synthesized Xanthines can potentially alleviate symptoms and improve the treatment of chronic inflammatory airway diseases.

InChI:InChI=1/C9H15N3O2/c1-3-5-12-8(13)6-7(10)11(4-2)9(12)14/h6H,3-5,10H2,1-2H3

Upstream product

• 41862-09-3 1-ethyl-6-aminouracil 
• 107-08-4 1-iodo-propane 
• 879328-64-0 6-[1-aza-2-(dimethylamino)vinyl]-1-ethyl-3-propyl-1,3-dihydropyrimidine-2,4-dione 
• 1055299-66-5 6-[1-aza-2-(dimethylamino)vinyl]-1-ethyl-3-propyl-1,3-dihydropyrimidine-2,4-dione 
• 752222-78-9 N'-(3-ethyl-1,2,3,6-tetrahydro-2,6-dioxopyrimidin-4-yl)-N,N-dimethylformamidine 

Downstream Products

• 752222-79-0 6-amino-1-ethyl-5-nitroso-3-propylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension

This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A2B receptor antagonist to the patient.

METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS

The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

Method of wound healing using A2B adenosine receptor antagonists

The present invention relates to methods of wound healing using A2B adenosine receptor antagonists. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.